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ABSTRACT
Objective
To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.

Methods
Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria.  

Results
Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children) new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Sub-classification is performed using a classification tree. A probability cutoff of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) “probable IIM”, had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to “definite IIM”. A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy) rules out IIM, leaving a probability of ≥50 to <55% as “possible IIM”. 

Conclusions
The EULAR/ACR classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and pediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of “definite”, “probable”, and “possible” IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.
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Introduction 
Idiopathic inflammatory myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation [1]. The most common subgroups in adults are dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM) [2], and in children, juvenile DM (JDM).
	
The International Myositis Assessment and Clinical Studies Group (IMACS) has developed consensus on outcome measures and definitions of improvement to be used in clinical trials for myositis [3, 4]. A prerequisite for clinical trials and other clinical studies is the inclusion of well-defined patient groups. A wide variety of diagnostic or classification criteria for myositis are used [2, 5-16], but are generally derived empirically and not validated. The criteria of Bohan and Peter [7, 8] are most widely used, but have limitations. Because they do not clearly specify how to exclude other forms of myopathy, they may misclassify IBM patients as PM [13, 17-19], and muscular dystrophies with inflammation as myositis, and each criterion is not defined explicitly. New discoveries in the last decade, such as myositis-specific autoantibodies, that are associated with distinct clinical phenotypes [2, 20-22], may provide opportunities to improve the precision of classification, but have not been tested adequately [11, 23].

The aim of this project was to develop classification criteria for adult and juvenile IIM. The specific goal was to define the minimum essential, easily available clinical and laboratory features to: (i) distinguish IIM from mimicking conditions with high sensitivity and specificity, and (ii) distinguish the major subgroups of IIM.

Methods
Study design
The International Myositis Classification Criteria Project (IMCCP), an international collaboration with experts from adult and pediatric rheumatology, neurology, dermatology, epidemiology, and biostatistics was established in 2004 and followed the EULAR and ACR recommendations for development of classification criteria from that time or published soon thereafter [24, 25]. A steering committee (table S1) and a larger working committee with experts in IIM were formed (Appendix).

Experts using the nominal group technique [26-29] designed the study and validation experiments, assembled and defined candidate criteria from published myositis criteria [2, 5-16] and other characteristics of myositis, determined and assembled the IIM subgroup diagnoses and comparator conditions that were studied. A pilot study to assess the practicality of capturing the items showed a fair agreement of data availability from IIM and non-IIM cases (table S2), and input was obtained from experts in the IMACS network to maximize face and content validity [24, 25]. Ninety three variables (table S3) were selected by the steering committee for study in cases and comparators. A glossary and definitions were developed according to an ACR glossary [30, 31] (table S4). Data were abstracted from patients’ records and entered into a web-based database. 

Inclusion criteria for cases and comparators were: i) diagnosis for at least 6 months prior to study inclusion; ii) physician certainty of diagnosis – either known IIM or, as comparators, known non-IIM cases where myositis was considered in the initial differential diagnosis; iii) patients with the most recent and complete data were prioritized to acquire the most complete data in a consistent manner. A maximum of 40 cases and an equal number of comparators were collected from each center. 

The study was approved by ethics committees at each site.

Data analysis and candidate criteria selection
The association of each variable with the diagnosis (IIM, non-IIM) was assessed by odds ratios and tested with the Fisher’s exact test. The treating physician diagnosis was considered the gold standard for analysis. Three classification techniques were explored: (i) a sum-of-items model in which a patient was classified as a case if the patient had a specified number of items from a set of items; (ii) a probability-score model; and (iii) a classification tree. The ensuing candidate criteria were examined with respect to statistical performance and clinical relevance. Due to the observed superior discriminating performance of the probability-score model, the other models were set aside. 

Criteria development
The probability-score model summed score points associated with the signs and symptoms present. The score points were obtained as coefficients of a logistic regression model used to combine multiple variables for predicting IIM. The statistical significance of the resulting increase in the goodness-of-fit of the model was assessed using the Wald test. The improvement in predictive ability was measured by the increment in specificity and sensitivity and summarized by the area under the receiver operating characteristic curve (AUC). 

Pediatric experts are using fewer muscle biopsies for classification of JDM in clinical practice than adult rheumatologists. Thus, a second model not including biopsy variables was developed. Assessment of statistical performance for each score/probability cutoff value provided the basis for a recommendation of a cutoff value for IIM classification by the steering committee. The proposed cutoffs were then defined as possible, probable and definite IIM. To facilitate use of the new criteria, a web-based calculator for the probability-score model was developed.

The new classification criteria were compared to previous IIM criteria. Their statistical performance was calculated and number of patients per IIM sub-diagnosis classified as IIM by the different criteria sets. 

To distinguish subgroups of patients classified with IIM according to the new criteria a classification tree was developed. The tree was based on the variables in the new classification criteria and on expert opinion. 

Validation
The new criteria were internally cross-validated. Samples of equal size to the original sample were drawn from the entire population at random with replacement, so-called “bootstrap” samples [32]. The bootstrap sample represented the training sample, and the remaining subjects not contained in the bootstrap sample constituted the validation sample. The probability score was applied to each bootstrap training sample separately and then utilized to predict IIM in the validation sample. The procedure was repeated in over 200 bootstrap samples, and the average AUC was calculated. 

The performance of the new criteria for IIM was tested for sensitivity in two independent cohorts, the Euromyositis Register (https://euromyositis.eu/ (​https:​/​​/​euromyositis.eu​/​​)) and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) (https://www.juveniledermatomyositis.org.uk/ (​https:​/​​/​www.juveniledermatomyositis.org.uk​/​​)). 

The program Stata v13 (StatCorp, College Station, TX, USA) was used for data management and statistical analyses. The statistical program R (R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/) was utilized for some analyses. 

A report detailing the methodology will be submitted as a separate publication (manuscript in preparation).

Results
Study population
Data from 976 IIM patients (74.5% adults; 25.5% children) (Table 1) were collected between 2008 and 2011 from 23 European, 17 North American, one South American, and six Asian sites, representing IIM subgroups of: JDM (n=248), PM (n=245), DM (n=239), IBM (n=176), amyopathic DM (ADM) (n=44), hypomyopathic DM (n=12), immune-mediated necrotizing myopathy (IMNM) (n=11) and juvenile PM (n=1). A total of 624 comparators (81.6% adults; 18.4% children) (Table 1) representing a broad spectrum of conditions that can mimic IIM were included, comprising systemic inflammatory diseases (36.5%), muscle dystrophies (16.0%), drug- or toxin-associated myopathies (7.9%), motor neuron diseases/neuropathies (7.7%), metabolic myopathies (6.9%), myalgias (4.5%), dermatologic diseases (3.7%), endocrine myopathies (3.7%), infectious myopathies (4.5%), mitochondrial myopathies (2.4%), neuromuscular diseases (2.6%), other myopathies (1.9%), immune-mediated skin conditions (0.5%), as well as other diagnoses (1.3%) (Table S5, S6). 

Table 1. Demographic data of the International Myositis Classification Criteria Project cohort 
	IIM(n=976)	Comparators(n=624)
Sex, n (%)    Female    Male	652 (66.8)324 (33.2)	369 (59.1)255 (40.9)
Adult onset disease*, n (%)Childhood onset disease*, n (%)	727 (74.5)249 (25.5)	509 (81.6)115 (18.4)
Age at onset of symptom, median (IQR), years	44.0 (14.7-57.0)	41.0 (20.0-56.0)
Age at diagnosis, median (IQR), years	45.5 (16.2-59.3)	45.0 (25.8-58.0)
Disease duration from time of first symptom†, median (IQR), years	4.0 (2.0-8.0)	4.0 (1.0-9.0)
Disease duration from time of diagnosis‡, median (IQR), years	3.0 (1.0-6.0)	1.8 (0.0-4.5)
Ethnicity, n (%)    Caucasian    Asian    Hispanic    African    Native American    Pacific Island    Mixed    Unknown	611 (62.6)177 (18.1)51 (5.2)40 (4.1)18 (1.8)3 (0.3)37 (3.8)54 (5.5)	360 (57.7)156 (25.0)25 (4.0)28 (4.5)4 (0.6)1 (0.2)22 (3.5)32 (5.1)
Disease onset§, n (%)    Acute (days to 2 weeks)    Subacute (> 2 weeks to ≤ 2 months)    Insidious (> 2 months to years)    NA	45 (4.6)237 (24.3)648 (66.4)46 (4.7)	64 (10.3)88 (14.1)444 (71.2)28 (4.5)
* Onset of first symptoms assumed to be related to the disease
† Time from first symptom to last clinical evaluation
‡ Time from diagnosis to last clinical evaluation  
§ Onset and progression of the first symptoms of the syndrome to the full disease presentation
IIM, idiopathic inflammatory myopathies; IQR, interquartile range; NA, information not available


Candidate criteria selection and criteria development
Based on statistical models, 16 variables from six categories best distinguished IIM cases from comparators (Table 2) and each variable was assigned a weight (score) based on its influence to discriminate IIM from non-IIM. A total score was computed by adding score points corresponding to each criterion being present. The score can be converted into a probability of IIM (Figure 1A, B) by:
Probability of IIM including muscle biopsy = 1 / [1 + exponential (5.33– score)] or, 
Probability of IIM without muscle biopsy = 1 / [1 + exponential (6.49– score)]

or by utilizing the online web-calculator (www.imm.ki.se/biostatistics/calculators/iim (​http:​/​​/​www.imm.ki.se​/​biostatistics​/​calculators​/​iim​)). 
Sensitivity and specificity for varying probability cutoffs are shown in Figure 1 (C, D). 

Cut-points for classification
The best balance between sensitivity and specificity was found for a probability of 55-60% for the criteria not including muscle biopsy data, and 55-75% when including muscle biopsies, or a total aggregated score of score of ≥5.5 and ≤ 5.7 (≥6.7 and ≤ 7.6 if biopsy is available). The IMCCP proposes that a patient may be classified as IIM if the probability exceeds a predetermined cutoff of at least 55% (corresponding to a score of ≥5.5, or ≥6.7 if biopsies are included) based on maximization of statistical performance and best balance between sensitivity and specificity. The level of probability ≥55% and <90% was defined as “probable IIM”.  The Steering committee recommends, based on expert opinion, that “definite IIM” should equal a probability of ≥90%, corresponding to having total aggregate score of  ≥7.5 without muscle biopsy and  ≥8.7 with muscle biopsy. 

Patients falling in the probability range ≥50% and <55% will be classified as “possible IIM”. For a patient to be classified as a non-IIM patient the probability would have to be <50% (score of maximum 5.3 without biopsies; 6.5 with biopsies).

As suggested by pediatric experts and dermatologists, for patients with pathognomonic skin rashes of DM or JDM, classification criteria were developed which did not include muscle biopsy data (Table 2). However, where no skin rash is present, a muscle biopsy is required for diagnosis, as determined by a consensus of expert opinion within the IMCCP steering and working committees. Both sets apply equally well to adult IIM patients and to juvenile dermatomyositis patients and should be used when IIM is suspected and no better explanation for the symptoms exists, as agreed upon by expert opinion. Definitions for the criteria items are presented in table 2.

Table 2. The EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies
When no better explanation for the symptoms and signs exists these classification criteria can be used
Variable	Score Points	Definition
	Without muscle biopsy	With muscle biopsy	
Age of onset of first symptom assumed to be related to the disease ≥ 18 years and < 40 years	1.3	1.5	18 ≤ Age (years) at onset of first symptom assumed to be related to the disease < 40
Age of onset of first symptom assumed to be related to the disease ≥ 40 years	2.1	2.2	Age (years) at onset of first symptom assumed to be related to the disease ≥ 40
Muscle weakness		
Objective symmetric weakness, usually progressive, of the proximal upper extremities	0.7	0.7	Weakness of proximal upper extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time
Objective symmetric weakness, usually progressive, of the proximal lower extremities	0.8	0.5	Weakness of proximal lower extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time
Neck flexors are relatively weaker than neck extensors	1.9	1.6	Muscle grades for neck flexors are relatively lower than neck extensors as defined by manual muscle testing or other objective strength testing
In the legs proximal  muscles are relatively weaker than distal muscles	0.9	1.2	Muscle grades for proximal muscles in the legs are relatively lower than distal muscles in the legs as defined by manual muscle testing or other objective strength testing
Skin manifestations		
Heliotrope rash	3.1	3.2	Purple, lilac-colored or erythematous patches over the eyelids or in a periorbital distribution, often associated with periorbital edema
Gottron´s papules	2.1	2.7	Erythematous to violaceous papules over the extensor surfaces of joints, which are sometimes scaly. May occur over the finger joints, elbows, knees, malleoli and toes
Gottron’s sign	3.3	3.7	Erythematous to violaceous macules over the extensor surfaces of joints, which are not palpable
Other clinical manifestations		
Dysphagia or esophageal dysmotility	0.7	0.6	Difficulty in swallowing or objective evidence of abnormal motility of the esophagus
Laboratory measurements		
Anti-Jo-1 (anti-histidyl-tRNA synthetase) autoantibody present 	3.9	3.8	Autoantibody test in serum performed with standardized and validated test, showing positive result
Elevated serum levels of creatine kinase (CK)* or lactate dehydrogenase (LDH)* oraspartate aminotransferase (ASAT/AST/SGOT)* oralanine aminotransferase (ALAT/ALT/SGPT)*	1.3	1.4	The most abnormal test values during the disease course (highest absolute level of enzyme) above the relevant upper limit of normal
Muscle biopsy features- presence of:			
Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibres		1.7	Muscle biopsy reveals endomysial mononuclear cells abutting the sarcolemma of otherwise healthy, non-necrotic muscle fibers, but there is no clear invasion of the muscle fibers
Perimysial and/or perivascular infiltration of mononuclear cells		1.2	Mononuclear cells are located in the perimysium and/or  located around blood vessels (in either perimysial or endomysial vessels)
Perifascicular atrophy		1.9	Muscle biopsy reveals several rows of muscle fibers which are smaller in the perifascicular region than fibers more centrally located
Rimmed vacuoles		3.1	Rimmed vacuoles are bluish by Hematoxylin and Eosin staining and reddish by modified Gomori- Trichrome stains
* Serum levels above the upper limit of normal 

Identification of subgroups
A patient classified with IIM by the EULAR/ACR classification criteria can be further sub-classified with a classification tree (Figure 2). Age at onset of first symptom (≥18 years of age) distinguishes adult from juvenile IIM. Thereafter, clinical findings and muscle biopsy features sub-classify adult IIM patients into PM, IBM, ADM or DM. Based on our data set juvenile patients with skin rash can be classified into JDM. Three subgroups cannot be further separated using our criteria because of small sample sizes: juvenile PM, IMNM, and hypomyopathic DM. 

Among patients with IIM by the EULAR/ACR classification criteria, and with sufficient data to allow sub-classification (n=703), the number of cases in the subgroups as defined according to the classification tree was enumerated (Table 3). The agreement between the classification tree subgroups and the physician-diagnosed subgroups in the dataset was high (92.6% agreement, kappa=0.90, p<0.00001). The agreement proportions, with a probability of 55%, were 1.00 for JDM, 0.89 for DM, 0.94 for ADM, 0.92 for IBM, and 0.93 for PM. Raising the probability cutoff of IIM to 90% yielded 94.9% agreement, kappa=0.93, p<0.00001. With a probability cutoff of 90% the agreement proportions were 1.00 for JDM, 0.96 for DM, 0.95 for ADM, 0.93for IBM, and 0.88 for PM. 

Table 3. Comparison of physician-diagnosed idiopathic inflammatory myopathies (IIM) subgroups with IIM subgroups defined according to the classification tree among patients meeting the EULAR/ACR classification criteria for IIM 

Physician-diagnosed subgroups	Classification tree subgroups*	Total
	JDM	DM	ADM	IBM	PM	
JDM	235	0	0	0	0	235
DM	0	191	6	2	15	214
ADM	1	1	30	0	0	32
IBM	0	0	0	66	5	71
PM	0	7	0	3	131	141
IMNM	0	0	0	0	10	10
Total	236	199	36	71	161	703
% of all IIM	33.6	28.3	5.1	10.1	22.9	
% of adult IIM	-	42.6	7.7	15.2	34.5	

* Classification of IIM by the EULAR/ACR classification criteria for IIM, using a 55% probability cutoff for classification, followed by the classification tree for sub-classification. 
JDM, juvenile dermatomyositis; DM, dermatomyositis; ADM, amyopathic dermatomyositis; IBM, inclusion body myositis; PM, polymyositis; IMNM, immune-mediated necrotizing myopathy.

Performance of EULAR/ACR criteria compared to published criteria 
Performance of the EULAR/ACR criteria was compared to published criteria for IIM [7,8,10,11,14,15] using the IMCCP dataset. The new criteria including muscle biopsy features displayed high sensitivity (93%) and specificity (88%). There was slightly lower performance without biopsy variables (sensitivity and specificity 87% and 82%, respectively). Among the assessed criteria, the Targoff criteria [11] showed the highest sensitivity (93%) and specificity (89%). Other criteria had either high sensitivity and low specificity (Bohan and Peter [7, 8] and Tanimoto criteria [10]), or low sensitivity and high specificity (Dalakas and Hohlfeld [14] and ENMC criteria [15]). 

We studied how different criteria could classify patients with diverse IIM sub-diagnoses in the IMCCP dataset (table 4). The EULAR/ACR classification criteria correctly classified most patients with all IIM sub-diagnoses. When biopsy data were used, the performance improved for IBM (94% with biopsy data vs. 58% without biopsy data) and PM (86% with biopsy data vs. 79% without biopsy data). The Bohan and Peter [7, 8], Tanimoto [10] and Targoff [11] criteria correctly classified all IIM sub-diagnoses except ADM, a diagnosis not included in those criteria. The Dalakas and Hohlfeld criteria [14] could not classify any sub-diagnoses. The ENMC criteria [15] correctly classified DM and JDM cases but no other sub-diagnoses. 

Table 4. Performance of the EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) and existing classification and diagnostic criteria for IIM 
PERFORMANCE(%)	The EULAR/ACR classification criteria for IIM*	Bohan and Peter† [7, 8]	Tanimoto et al. [10]	Targoff et al.† [11]	Dalakas and Hohlfeld† [14]	ENMCHoogendijk et al.† [15]
	Without muscle biopsy 	With muscle biopsy					
Mean (95% CI)Sensitivity	87(84-90)	93(89-95)	98(96-99)	96(94-97)	93(90-95)	6(5-8)	52(48-55)
Specificity	82(77-87)	88(83-93)	55(50-61)	31(25-37)	89(84-92)	99(98-100)	97(95-98)
MeanPositive predictive valueNegative predictive value	9079	9485	8590	8073	9585	9243	9657
Correctly classified	86	91	86	79	91	45	70
CORRECTCLASSIFICATION OF IIMPER SUBGROUP‡ (%)
Amyopathic dermatomyositis	94	60	25	14	0	0	0
Dermatomyositis	96	98	100	96	99	7	83
Hypomyopathic dermatomyositis	83	100	80	40	67	0	20
Immune-mediated necrotizing myopathy	100	100	100	100	100	0	10
Inclusion body myositis	58	94	97	97	91	1	1
Juvenile dermatomyositis	97	96	100	96	98	5	86
Polymyositis	79	86	95	100	85	11	9
							
* Cutoff for probability: 55%
† Definite and probable polymyositis and dermatomyositis
‡ Classification as idiopathic inflammatory myopathy per subgroup out of total number of cases per subgroup, expressed as mean
IIM, idiopathic inflammatory myopathies; ENMC, European Neuromuscular Centre; CI, confidence interval 

A comparison between the EULAR/ACR classification criteria (55% probability cutoff) and the Bohan and Peter criteria [7, 8] showed 89% agreement (kappa=0.71, p<0.00001) without including muscle biopsy data, and 93% agreement (kappa=0.73, p<0.00001) using muscle biopsy findings. Comparison between the newly-developed criteria and the Targoff criteria [11] demonstrated that the agreement was 89% (kappa=0.74, p<0.00001) and 93% (kappa=0.82, p<0.00001) without or with inclusion of muscle biopsy data, respectively. 

Validation 
Internal validation
Using the criteria without muscle biopsy data, 733 observations were used, resulting in AUC=0.942 and cross-validated area=0.933. Using the criteria with muscle biopsy data, 507 observations were included, resulting in AUC=0.962 and cross-validated area=0.942. 

External validation for sensitivity
Data from 592 cases (PM=281, DM=256, IBM=33, JDM=18 and ADM=4) in the Euromyositis register were used where clinical, laboratory and muscle biopsy data were available (Karolinska University Hospital, Stockholm, Sweden; Prague Hospital, Prague, Czech Republic; Oslo University Hospital, Oslo, Norway) (table S7). When there was sufficient information available, the EULAR/ACR classification criteria confirmed IIM diagnosis using a 55% probability cutoff for classification of IIM with no misclassification, yielding 100% sensitivity. Using the criteria without muscle biopsies, 489 (83%) patients were classified as IIM, and 103 (17%) patients could not be classified due to missing data. For the criteria with biopsies, 204 (34%) were classified as IIM and 388 (66%) could not be classified due to missing muscle biopsy data in the register. Results for the IBM and PM subgroups improved when biopsy data were included: 97% of IBM cases could be classified compared to 73% when biopsy data were not included. For PM, 80% and 76% respectively could be classified. Raising the IIM classification cutoff from 55% to 90% decreased the total number of cases that could be classified to only 63% (not including muscle biopsies) or 28% (including muscle biopsies) due to absence of some muscle biopsy variables in the Euromyositis registry data-base. 

The Juvenile Dermatomyositis Biomarker Study and Repository (UK and Ireland) 
The JDRG register included 332 juvenile IIM cases in the study (definite JDM=292, probable JDM=20, definite juvenile PM=4, probable juvenile PM=2, focal myositis=6 and other IIM=8) (table S8). Muscle biopsy data were not available for all, thus the EULAR/ACR classification criteria without muscle biopsy data were used to test sensitivity in this dataset. Three hundred and seven (92%) cases could be classified using the 55% cutoff and no case was misclassified, yielding 100% sensitivity. The remaining 25 cases (8%) could not be classified due to missing data. Raising the cutoff stepwise to 60%, 70%, 80% or 90% yielded classification of 92%, 88%, 87% or 64% cases respectively, where classification was possible.

Web-calculator 
A web-calculator was developed (www.imm.ki.se/biostatistics/calculators/iim (​http:​/​​/​www.imm.ki.se​/​biostatistics​/​calculators​/​iim​)) as an aid to use the EULAR/ACR classification criteria. A probability range of classification can be obtained, providing the minimum and maximum probability. In addition to the probabilities acquired, the aggregated scores will be displayed. Whenever sufficient data are entered, the sub-classification will be displayed. 

Discussion
Classification criteria are essential for inclusion of comparable patients in studies. No validated classification criteria for IIM currently exist. The EULAR/ACR classification criteria for IIM offer advantages that previous criteria lack. They are data-driven, exhibit high sensitivity and specificity, and use a limited number of accessible, defined clinical and laboratory variables. Internal validation and testing in external cohorts confirmed excellent performance. Importantly, the new criteria capture the most frequent IIM subgroups and can be used for both adults and children for research studies and clinical trials.  

The new EULAR/ACR classification criteria provide a score with a corresponding probability of having IIM. This provides investigators flexibility in inclusion criteria for different types of studies, e.g. clinical trials requiring high specificity would warrant a high probability of IIM in the inclusion criteria, whereas epidemiological studies requiring high sensitivity would need inclusion criteria with lower probability or IIM. 

The new criteria are based on data from children and adults with different ethnicities from centers in Europe, America and Asia, and use symptoms, signs and other measures that are routinely assessed. Importantly, in patients with a typical DM skin rash, the criteria can be used without muscle biopsy data. For JDM, 97% of patients were correctly classified using the new criteria without muscle biopsy data. The new criteria also offer practical advantages in the number of variables needed to be tested. If a sufficient probability is reached, there is no requirement to test all items. Each criterion is well-defined, lessening the opportunities for ad hoc interpretation. The skin rash typical of DM contributed with high weights in the probability score. Skin biopsy is recommended in the absence of muscle symptoms [33, 34]. The EULAR/ACR classification criteria are the first myositis criteria to be validated and tested for sensitivity in other cohorts and revealed no misclassification.   

Compared to most previous criteria, the new criteria are superior in sensitivity, specificity and classification accuracy. Classification criteria should have high sensitivity and specificity. The EULAR/ACR criteria demonstrated sensitivity and specificity of 87% and 82% respectively, with even higher accuracy when muscle biopsies were included, 93% and 88% respectively. Correctly classified patients were 86% and 91% respectively with and without inclusion of biopsies, and the criteria performed equally well for adult and juvenile cases. The Targoff criteria [11] also showed good statistical properties, but were not able to capture all subgroups of IIM as ADM patients were not included. Furthermore, the variables were not clearly defined in the Targoff criteria, and testing of more variables is required, including electromyography, which is not always easily accessible and may be painful for patients. Importantly, the EULAR/ACR criteria can be applied to myositis patients with overlap diagnoses, such as mixed connective tissue disease or systemic lupus erythematosus with myositis, since these patients were included among IIM cases. 

There are limitations of the study; no controls or comparators were included in the external validation cohort, since the IMCCP study was designed before those recommendations from ACR/EULAR were in place, requiring future validation. Another limitation largely unavoidable in observational data is the high frequency of missing data in the derivation dataset and validation samples, reflecting differences in practice patterns in evaluating patients. Nevertheless, 80% of cases and comparators had muscle biopsy data available, whereas magnetic resonance imaging data and electromyography were only available for 38% and 29% of cases respectively, reflecting their limited usage in clinical. However, magnetic resonance imaging data and electromyography examination are still important for diagnostic purposes of IIM. Patients studied had to have their disease for at least 6 months, which did not allow us to study new-onset patients. Importantly, these criteria are proposed as classification criteria in research and in clinical trials, not as diagnostic criteria [35]. There is also some possibility that the cut-points established for probable and definite myositis will need adjustment when tested with new populations of patients.

It took almost 10 years to assemble sufficient numbers of patients with these rare diseases and three subgroups did not have enough subjects to study adequately. During this period a new IIM subgroup became recognized, IMNM [36], of which only a few cases were included into the study. IMNM cases could thus not be distinguished from PM in the sub-classification tree. Another subgroup with few cases was juvenile PM, making a data-derived distinction from JDM impossible. However, pediatric rheumatology experts in the IMCCP recommended that the adult sub-classification of IIM could be used for juvenile PM by extrapolation (Figure 2). IBM cases were identified in the sub-classification tree by the clinical features of finger flexor weakness and no response to treatment, OR by the presence of rimmed vacuoles in muscle biopsies [37]. 

Another limitation was the low frequency of myositis-specific autoantibodies documented. Five myositis-specific autoantibodies were included: anti-Jo-1, anti-Mi-2, anti-SRP, anti-PL7 and anti-PL12 antibodies and all were strongly associated with IIM. However, only anti-Jo-1 autoantibody had a significant number of observations (n=1,062) to permit analyses and inclusion in the classification criteria. A future update of the EULAR/ACR classification criteria should include the more recently-identified myositis-specific autoantibodies [21,22], in addition to more patients with IMNM, ADM, hypomyopathic DM and juvenile cases other than JDM. 

Recommendations
	Patients with pathognomonic skin rashes (heliotrope rash, Gottron’s papules and/or Gottron’s sign) of JDM or DM are accurately classified with the EULAR/ACR classification criteria without including muscle biopsy data. For patients without these skin manifestations muscle biopsy is recommended. For DM patients without muscle involvement a skin biopsy is recommended. 
	The EULAR/ACR classification criteria provide a score and a corresponding probability of having IIM. Each probability displays a unique sensitivity and specificity. The best balance between sensitivity and specificity can be found for a probability of 55-60% (total aggregated score of ≥5.5 and ≤ 5.7) for the criteria not including muscle biopsy data, and 55-75% (total aggregated score ≥6.7 and ≤ 7.6) when including muscle biopsies. These cases are designated “probable IIM”. The recommended cutoff needed for classifying a patient as IIM is ≥55%. 
	“Definite IIM” corresponds to a probability of ≥90% or a total aggregate score of 7.5 or more without muscle biopsy and 8.7 with muscle biopsy, and is recommended in studies where a high specificity is required.
	A patient is termed “possible IIM” if the probability is ≥50% and <55% (a minimum score of 5.3 without biopsies and 6.5 with biopsies). 
	For clarity and transparency, both the descriptive term (“possible”, “probable” or “definite”) and the probability and the aggregated score should be reported in studies. 

Conclusions
New classification criteria for IIM and the major IIM subgroups have been developed. These data-driven criteria have a good feasibility, high sensitivity and specificity, have been partly validated in external cohorts, and are superior to previous criteria in capturing different subgroups of IIM. Revision of the criteria in the future will be important when additional validated myositis autoantibody tests, imaging and other tests are available in more IIM cases and comparator cases without IIM.  

Appendix
We are grateful for contribution of clinical data from investigators, and for participants contributing with valuable input at IMCCP meetings (Appendix). 
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Figure legends

Figure 1. Probability of having idiopathic inflammatory myopathies (IIM) based on the EULAR/ACR classification criteria for IIM. Each score obtained from the classification criteria corresponds to a probability of having the disease, without muscle biopsy data (A), or with muscle biopsy data (B). Each score and probability of disease display a unique set of sensitivity (blue line) and specificity (red line) measurements for the classification criteria not including muscle biopsy data (C) or including muscle biopsy data (D). The most optimal point of accuracy should be stated in publications and be appropriate to the intended purpose, with the recommendation of using a minimum of 55% probability (score of 5.5 without biopsies; 6.7 with biopsies) for classifying a case as IIM (“probable IIM”) (dotted line). “Definite IIM” corresponds to a probability of at least 90% (score of 7.5 without biopsies; 8.7 with biopsies). 

Figure 2. Classification tree for subgroups of idiopathic inflammatory myopathies (IIM). A patient must first meet the EULAR/ACR classification criteria for IIM. The patient can then be sub-classified using the classification tree. The subgroup of PM patients includes patients with immune-mediated necrotizing myopathy (IMNM). For IBM classification one of the following, *Finger flexor weakness and response to treatment: not improved, or **Muscle biopsy: rimmed vacuoles, is required for diagnosis. ***Juvenile myositis other than JDM was developed based on expert opinion. IMNM and hypomyopathic DM were too few to allow sub-classification.
PM, polymyositis; IMNM, immune-mediated necrotizing myopathy; IBM, inclusion body myositis; ADM, amyopathic dermatomyositis; DM, dermatomyositis; JDM, juvenile dermatomyositis. 
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